New Results Will Change the Paradigm for Phase I Trials and Drug Approval
نویسنده
چکیده
Disclosures: Bruce A. Chabner: Employment/leadership position: Massachusetts General Hospital, Harvard; Consultant/advisory role: Sanofi, Redwood, Allergan, Epizyme, PharmaMar, GSK (Pending); Honoraria: Eli Lilly; Research funding/contracted research: U.S. Government; Ownership interest: PharmaMar, Gilead, Merck, Epizyme, Human Genome Sciences, Curis, Onyx, Rigel, Bristol-Myers. The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the independent peer reviewers.
منابع مشابه
Statistical Challenges with the Advances in Cancer Therapies
Statistical challenges in designing, analyzing and interpreting the data are being encountered with the recent development of new classes of drugs to treat cancer. The existing paradigm of drug development from Phase I to Phase III clinical trials is not optimal. New and innovative trial designs and statistical methods are needed to evaluate the new classes of drugs. In this chapter we present ...
متن کاملRedefining cancer: a new paradigm for better and faster treatment innovation.
Common cancers may arise from several different mutations, and each causative mutation may require different treatment approaches. There are also several mechanisms by which malignancies may become resistant to therapy, and each mechanism will also require a different therapeutic strategy. Hence, the paradigm of devising therapies based on tumor type is suboptimal. Each common malignancy may no...
متن کاملTransforming Drug Development in Heart Failure
Based on favorable hemodynamic data, flosequinan, an oral vasodilator, received marketing approval in Europe in September 1992 and in the United States in March 1993 for use in chronic heart failure (HF). Later, a phase III trial signaled increased mortality, prompting its withdrawal from the market. Oral milrinone was initially used for refractory HF but was later shown to increase adverse eve...
متن کاملObjective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval.
PURPOSE Tumor responses in early-phase trials are used to determine whether new agents warrant further study. Given that spontaneous regressions are observed in melanoma and renal cell carcinoma, this study assessed whether tumor responses, particularly in these two tumor types, predict for future regulatory drug approval. EXPERIMENTAL DESIGN The literature was reviewed to assess tumor respon...
متن کاملO12: Off the Couch and Out the Door: Improving Treatment Through a Refined Understanding of Psychotherapeutic Change
State-of-the-art psychotherapy for anxiety disorders represents some of the most efficacious treatments in the mental health literature. Nevertheless, these treatments are not panacea. Too many patients drop out of treatment, response rates leave room for improvement, and residual symptomatology is common. The quest to improve therapy for patients suffering from mental disorders necessitates on...
متن کامل